Chicago—The approval in 2006 of continuous glucose monitoring (CGM) devices brought hopes that providing patients with type 1 diabetes with real-time information from a sensor implanted just under the skin would allow them to achieve better glycemic control. However, researchers have had a tough time showing efficacy of CGM in the clinic due to such factors as problems with device calibration and a lack of rigorous trial data.
A study presented at the American Diabetes Association’s 67th Scientific Sessions, held here in June, suggests that yet another element may limit how well CGM translates into glycemic control: patients who are indifferent to taking action to adjust their blood glucose level based on the information generated by CGM.
Mitka M. Poor Patient Adherence May Undermine Aim of Continuous Glucose Monitoring. JAMA. 2007;298(6):614–615. doi:10.1001/jama.298.6.614
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: